Company registration number 03935855 (England and Wales)
TRANSMEDICA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
PAGES FOR FILING WITH REGISTRAR
TRANSMEDICA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
TRANSMEDICA LIMITED
BALANCE SHEET
AS AT
28 FEBRUARY 2024
28 February 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investment property
3
1,400,000
1,650,000
Current assets
Debtors falling due after more than one year
4
33,997
32,343
Debtors falling due within one year
4
1,348
2,371
Cash at bank and in hand
5,661
7,507
41,006
42,221
Creditors: amounts falling due within one year
5
(175,311)
(933,833)
Net current liabilities
(134,305)
(891,612)
Total assets less current liabilities
1,265,695
758,388
Creditors: amounts falling due after more than one year
6
(717,420)
(656,252)
Provisions for liabilities
(105,719)
-
0
Net assets
442,556
102,136
Capital and reserves
Called up share capital
7
2
2
Profit and loss reserves
442,554
102,134
Total equity
442,556
102,136
TRANSMEDICA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
28 FEBRUARY 2024
28 February 2024
- 2 -

For the financial year ended 28 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 27 November 2024 and are signed on its behalf by:
J P Patel
Director
Company registration number 03935855 (England and Wales)
TRANSMEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 3 -
1
Accounting policies
Company information

Transmedica Limited is a private company limited by shares incorporated in England and Wales. The registered office is 112 Guildhall Street, Folkestone, Kent, CT20 1ES.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include investment properties at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the company had sold further investment properties. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future due to their continued financial support.true

 

Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover represents rents receivable prior to the balance sheet date.

1.4
Investment properties

Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. The surplus or deficit on revaluation is recognised in the profit and loss account.

1.5
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

TRANSMEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
1
Accounting policies
(Continued)
- 4 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

TRANSMEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
1
Accounting policies
(Continued)
- 5 -
1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
3
3
3
Investment property
2024
£
Fair value
At 1 March 2023
1,650,000
Additions
9,000
Disposals
(396,848)
Revaluations
137,848
At 28 February 2024
1,400,000
TRANSMEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
3
Investment property
(Continued)
- 6 -

Investment property comprises of commercial properties with a fair value of £1,400,000. The fair value of the investment property has been determined by reference to the open market value basis by reference to market evidence of transaction prices for similar properties.

4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Other debtors
1,348
2,371
2024
2023
Amounts falling due after more than one year:
£
£
Other debtors
33,997
32,343
Total debtors
35,345
34,714
5
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
128,341
886,723
Trade creditors
45,032
44,864
Other creditors
1,938
2,246
175,311
933,833

The bank loans are secured by a fixed and floating charge over the company's assets.

6
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans
13,956
23,855
Other creditors
703,464
632,397
717,420
656,252

The bank loans are secured by a fixed and floating charge over the company's assets.

 

TRANSMEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 7 -
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
2
2
2
2
8
Non-distributable profits reserve
2024
2023
£
£
At the beginning of the year
661,094
494,196
Non distributable profits in the year
32,129
166,898
At the end of the year
693,223
661,094
9
Financial commitments, guarantees and contingent liabilities

During the year, a cross guarantee existed between Transmedica Limited and Ampersand Care Limited in favour of the bankers of Ampersand Care Limited. The maximum potential liability as at 28 February 2024 was £nil (2023: £1.275m), as Ampersand Care Limited was dissolved on 4 August 2023.

10
Directors' transactions

Included within other creditors are interest free loans from the directors amounting to £690,595 (2023: £618,528).

2024-02-282023-03-01falsefalsefalse27 November 2024CCH SoftwareCCH Accounts Production 2024.310No description of principal activityJ P PatelDr J P PatelR PatelJ P Patel039358552023-03-012024-02-28039358552024-02-28039358552023-02-2803935855core:Non-currentFinancialInstrumentscore:AfterOneYear2024-02-2803935855core:Non-currentFinancialInstrumentscore:AfterOneYear2023-02-2803935855core:CurrentFinancialInstrumentscore:WithinOneYear2024-02-2803935855core:CurrentFinancialInstrumentscore:WithinOneYear2023-02-2803935855core:CurrentFinancialInstruments2024-02-2803935855core:CurrentFinancialInstruments2023-02-2803935855core:Non-currentFinancialInstruments2024-02-2803935855core:Non-currentFinancialInstruments2023-02-2803935855core:ShareCapital2024-02-2803935855core:ShareCapital2023-02-2803935855core:RetainedEarningsAccumulatedLosses2024-02-2803935855core:RetainedEarningsAccumulatedLosses2023-02-2803935855bus:CompanySecretaryDirector12023-03-012024-02-28039358552022-03-012023-02-28039358552023-02-2803935855core:WithinOneYear2024-02-2803935855core:WithinOneYear2023-02-2803935855core:AfterOneYear2024-02-2803935855core:AfterOneYear2023-02-2803935855bus:PrivateLimitedCompanyLtd2023-03-012024-02-2803935855bus:FRS1022023-03-012024-02-2803935855bus:AuditExemptWithAccountantsReport2023-03-012024-02-2803935855bus:Director12023-03-012024-02-2803935855bus:Director22023-03-012024-02-2803935855bus:Director32023-03-012024-02-2803935855bus:CompanySecretary12023-03-012024-02-2803935855bus:SmallCompaniesRegimeForAccounts2023-03-012024-02-2803935855bus:FullAccounts2023-03-012024-02-28xbrli:purexbrli:sharesiso4217:GBP